MedWatch

A part of Watch Media

ALK awaits crucial adrenaline data in 2021 and plans to submit FDA application in less than three years

Allergy company ALK will receive crucial trial data from partner Windgap which is working on a next-generation adrenaline pen which ALK has the rights to. Meanwhile, ALK is developing its own adrenaline pen based on experiences with Jext. The firm is confident it will be submitting a registration application to the US FDA before 2024.

Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
BY ALBERT RØNNING_ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

ALK's allergy specialists want more than a dominant position in the US market for tablet treatments for patients with allergies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

  1. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  2. FDA approves new sensor for insulin pens
  3. Full house for Ambu – all products live up to new EU requirements
  4. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  5. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  6. New majority owner makes several board appointments at hearing firm
  7. FDA awards Pfizer's RSV vaccine candidate priority review status
  8. More countries back EU Commission investigation into potential Oticon sale
  9. Nobel Prize winner: "Good research is driven by curiosity"
  10. Forward Pharma's last hope in protracted Biogen battle extinguished
  11. FDA ruling to trigger royalty payments for Novo Nordisk
  12. Federal court throws out cancer cases against GSK, Sanofi and Pfizer
  13. Coloplast deputy chair spends USD 7m on shares in firm
  14. USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug
  15. Biogen and Sage complete FDA rolling submission of depression drug

See all

Job

See all jobs

See all jobs